ICOs Capital has announced an investment in Mevaldi B.V., a Dutch biotech firm specializing in sustainable biochemical building blocks. The funding aims to support Mevaldi’s efforts to increase production capacity and accelerate its commercial rollout. Alongside ICOs, High-Tech Gründerfonds and ICIG Ventures from Germany have also invested in the company.
Mevaldi is recognized for developing bio-based materials used in sustainable polymers and polyurethanes. Since 2020, the company has been working on 3MPD, a product derived from sugars and wood residues. This innovative material is produced via a patented bio-thermochemical process. Mevaldi’s focus is on creating high-performance, environmentally friendly materials at competitive prices, with all production based within Europe.
The company’s approach supports the European Union’s goals for strategic autonomy, circular economy, and climate action. The recent investment provides Mevaldi with resources to scale its operations efficiently and bring its products to more markets. The company aims to produce affordable chemical building blocks for various applications in the green economy.
ICOs Capital’s investment aligns with its strategy to support companies that can grow rapidly while maintaining cost efficiency. The firm values Mevaldi’s potential to deliver sustainable solutions that are scalable and market-ready. The investment also strengthens Mevaldi’s partnership with established industrial producers, facilitating low-cost, environmentally friendly production.
Peter van Gelderen, General Partner at ICOs, expressed enthusiasm about the investment. He highlighted Mevaldi’s attractive, CAPEX-light scale-up approach and its potential to serve multiple markets. Roger Ottenheym, CEO of Mevaldi, welcomed the new backing. He emphasized their plan to develop bio-based building blocks for existing and emerging applications, with the goal of reducing CO2 emissions at competitive costs.
The post Investment boost for Dutch biochemical producer Mevaldi appeared first on World Bio Market Insights.
